OssDsign enrolls the first patient to the multi-center prospective spinal fusion registry PROPEL in the U.S.
Uppsala, April 4, 2022. OssDsign AB (publ.) today announces that the first patient has been enrolled to the company’s multi-center, prospective spinal fusion registry in the U.S., PROPEL, with the objective to evaluate the use and outcome of OssDsign Catalyst in real-world clinical practice.The patient recruitment follows on the March 18 initiation of the first clinical site in PROPEL, a spinal fusion registry that initially will evaluate the rate of fusion, twelve months following treatment with the company’s nanosynthetic bone graft, OssDsign Catalyst. Additionally, the clinical safety